Bondeson, Daniel P.
Mullin-Bernstein, Zachary
Oliver, Sydney
Skipper, Thomas A.
Atack, Thomas C. http://orcid.org/0000-0001-5953-2261
Bick, Nolan
Ching, Meilani
Guirguis, Andrew A. http://orcid.org/0000-0003-3134-0596
Kwon, Jason
Langan, Carly
Millson, Dylan
Paolella, Brenton R. http://orcid.org/0000-0003-3394-828X
Tran, Kevin
Wie, Sarah J.
Vazquez, Francisca
Tothova, Zuzana
Golub, Todd R. http://orcid.org/0000-0003-0113-2403
Sellers, William R. http://orcid.org/0000-0002-3539-9803
Ianari, Alessandra
Funding for this research was provided by:
Center for Strategic Scientific Initiatives, National Cancer Institute (CA212229, CA242457, CA233626, CA233626, CA233626, CA233626, CA242457, CA233626, CA233626)
Article History
Received: 19 January 2022
Accepted: 8 September 2022
First Online: 20 September 2022
Competing interests
: F.V. receives research funding from Novo Ventures. T.R.G. has an equity interest in or receives consulting income from Sherlock Biosciences and Anji Pharmaceuticals and receives research funding from Calico Life Sciences, Bayer HealthCare, and Novo Holdings. A.I. receives cash compensation for consulting with Ridgeline Discovery. W.R.S. is a Board or SAB member and holds equity in Ideaya Biosciences, Civetta Therapeutics, Red Ridge Bio, and 2Seventy Bio and has consulted for Array, Astex, Epidarex Capital, Ipsen, PearlRiver Therapeutics, Merck Pharmaceuticals, Sanofi, Servier, and Syndax Pharmaceuticals and receives research funding from Pfizer Pharmaceuticals, Merck Pharmaceuticals, Ideaya Biosciences, Calico, Boehringer-Ingelheim, Bristol Myers Squibb, and Ridgeline Discovery. W.R.S. is a co-patent holder on EGFR mutation diagnostic patents. The remaining authors declare no competing interests.